Action ZYDUSLIFE ZYDUS LIFESCIENCES LIMITED
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Zydus Lifesciences Limited

Actions

ZYDUSLIFE

INE010B01027

Marché Fermé - NSE India S.E.
Autres places de cotation
 13:43:50 02/05/2024 		Varia. 5j. Varia. 1 janv.
988 INR +3,61% Graphique intraday de Zydus Lifesciences Limited +2,98% +43,35%
26/04 La faiblesse des bénéfices du trimestre de mars pèse sur les actions indiennes vendredi MT
26/04 Zydus Lifesciences obtient l'approbation finale de la FDA pour une crème générique contre l'acné MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Weak March Quarter Earnings Weigh Down Indian Equities on Friday
Zydus Lifesciences Gets US FDA's Final Approval for Generic Acne Cream
Zydus Lifesciences Gets 10 Observations from US FDA After Jarod, India Manufacturing Site Inspection
China Medical System's Anti-Anaemia NDA Accepted in China
Zydus Lifesciences' Desidustat Tablets Get Nod from China Regulator
Zydus Lifesciences Limited Announces New Drug Application of Zydus' Innovative Drug Desidustat Tablets by China Medical System Holdings Limited Accepted in China
Zydus launches Mirabegron Extended-Release Tablets in the US
Zydus Lifesciences Limited Launches Mirabegron Extended-Release Tablets in the U.S
Zydus Arm Get UK Drug Regulator's Marketing Approval for Nulibry as MoCD Type A Treatment
Zydus Lifesciences Launches Generic Drug for Overactive Bladder in US
Zydus Receives Approval from WHO International Non-Proprietary Names for Usnoflast as Recommended Name for ZYIL1
Zydus Gets Four Observations from US FDA for Oncology Injectable Plant
Zydus Lifesciences Limited Receives Tentative Approval from USFDA for Letermovir Tablets, 240 Mg and 480 Mg
Zydus Lifesciences Gets US FDA's Final Nod for Finasteride and Tadalafil Capsules
Zydus Lifesciences Limited Receives Final Approval from USFDA and 180 Days CGT Exclusivity for Finasteride and Tadalafil Cap Capsules
Tranche Update on Zydus Lifesciences Limited's Equity Buyback Plan announced on February 9, 2024.
Zydus Lifesciences Gets US FDA Final Nod for Chlorpromazine Hydrochloride Injection; Shares Jump 3%
Zydus Receives Final Approval from the USFDA for Chlorpromazine Hydrochloride Injection USP, 25 mg/mL and 50 mg/2 mL (25 mg/mL), Single-Dose Vials
Zydus Receives Tentative Approval from the USFDA for Edaravone Injection, 30 mg/100 mL (0.3 mg/mL), Single-Dose Vial
Zydus Lifesciences Launches Generic Cancer Drug Ibyra in India
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ZYDUSLIFE
  4. Actualités Zydus Lifesciences Limited
  5. Autres langues